Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Liquidia Corporation (NASDAQ: LQDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation focused on biopharmaceutical products for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), Liquidia uses these filings to report financial results, material agreements, governance changes and other significant events.
Investors can review Forms 10‑K and 10‑Q for detailed discussions of Liquidia’s business, including its PRINT® technology platform, the commercialization of YUTREPIA™ (treprostinil) inhalation powder, development of the investigational L606 treprostinil liposome inhalation suspension, and promotion of generic Treprostinil Injection under a profit‑sharing agreement with Sandoz. These periodic reports typically include segment information, research and development spending, risk factors related to PAH and PH‑ILD markets, and descriptions of key contracts.
Current reports on Form 8‑K highlight specific events such as quarterly earnings releases, financing transactions under the revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR), entry into the exclusive license with Vectura for the nebulizer device used with L606, leases for expanded manufacturing facilities in Morrisville, North Carolina, and outcomes of annual stockholder meetings. Other 8‑K filings may document executive appointments, compensation arrangements and other governance matters.
Users can also monitor proxy statements and Form 4 insider transaction reports to understand board elections, advisory votes on executive compensation and equity awards to officers and directors. Stock Titan’s interface combines these documents with AI‑powered summaries that explain complex sections of long filings, highlight key changes from prior periods and help clarify how new agreements, clinical developments or financing structures may affect Liquidia’s operations and capital structure.
With real‑time updates from EDGAR and structured access to historical filings, this page serves as a central resource for analyzing Liquidia’s regulatory history, capital markets activity and disclosures related to its treprostinil‑based therapies for PAH and PH‑ILD.
Liquidia (LQDA) reported insider activity by its Chief Business Officer. On 10/10/2025, the officer settled equity awards, converting 3,906 RSUs and 2,474 PSUs into common stock. On 10/13/2025, 3,670 shares were sold at $23.41 under a Rule 10b5-1 plan to cover taxes tied to those settlements. Following these transactions, the officer beneficially owned 175,690 common shares, held directly. RSUs and PSUs convert one-for-one into common stock, with remaining unvested awards continuing on their stated vesting schedules.
Liquidia Corp. (LQDA) insider activity: Chief Medical Officer Dr. Rajeev Saggar reported a PSU conversion and a tax-related sale. On 10/10/2025, 3,530 performance stock units converted into common stock on a one-for-one basis (code M). On 10/13/2025, 5,327 shares were sold at $23.41 (code S) pursuant to a Rule 10b5-1 plan adopted on December 15, 2023.
Following these transactions, the reporting person beneficially owns 247,930 shares, held directly. The sale was disclosed as covering taxes tied to the settlement of RSUs and PSUs initially granted on January 11, 2023 and January 11, 2024. The officer’s role is listed as Chief Medical Officer.
Liquidia (LQDA)10/13/2025, she sold 1,691 shares of common stock at $23.41 per share under a Rule 10b5-1 plan adopted on December 15, 2023. The sale covered taxes tied to RSU settlements from awards granted on January 11, 2024 and July 1, 2024.
After the trade, she beneficially owned 141,439 shares. Her holdings include unvested RSUs from 2024 and 2025 grants and 5,312 shares acquired under the 2020 ESPP.
Liquidia (LQDA) reported an insider transaction by its Chief Accounting Officer. On 10/13/2025, the officer sold 1,238 shares of common stock at $23.41 per share, coded “S,” pursuant to a Rule 10b5-1 plan adopted on December 15, 2023. The filing states the sale was to cover taxes tied to the settlement of restricted stock units granted on January 11, 2024.
After the transaction, the officer beneficially owned 185,411 shares, held directly. Holdings include unvested RSUs from prior grants and 11,869 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Liquidia Corp (LQDA) Chief Commercial Officer Scott Moomaw reported insider transactions. On 10/10/2025, 3,108 common shares were acquired upon settlement of performance stock units at $0 per unit. On 10/13/2025, 4,900 shares were sold at $23.41 pursuant to a Rule 10b5-1 plan; the filing notes the sale covered taxes related to prior RSU/PSU settlements.
Following these transactions, he beneficially owned 153,462 common shares directly and held 27,969 unvested RSUs.
Liquidia (LQDA): Form 4 insider activity — The company’s General Counsel reported a conversion of performance stock units and a tax-related sale. On 10/10/2025, 3,758 PSUs converted into an equal number of common shares. On 10/13/2025, 7,839 common shares were sold at $23.41, effected under a Rule 10b5-1 plan adopted on 12/15/2023 and to cover taxes associated with prior RSU and PSU settlements.
Following these transactions, the reporting person directly held 576,017 common shares and had 33,826 derivative securities (PSUs) beneficially owned. An additional 14,500 shares are held indirectly by a spouse. PSU and RSU grants vest on stated schedules, with one-for-one PSU conversion into common stock.
Liquidia (LQDA) officer Michael Kaseta (CFO and COO) reported a Form 4 showing equity settlement and a tax-related sale. On 10/10/2025, he acquired 5,828 shares of common stock upon the conversion of performance stock units, which convert one-for-one into common stock. On 10/13/2025, he sold 11,630 shares at $23.41 per share pursuant to a Rule 10b5-1 plan.
The filing states the sale was made to cover taxes from the settlement of previously granted RSUs and PSUs. Following the transactions, Kaseta beneficially owned 352,646 shares directly. The derivative table lists 52,453 derivative securities beneficially owned after the reported transactions.
Amendment corrects previously omitted indirect holdings: Dr. Stephen M. Bloch, a director of Liquidia Corp (LQDA), amended a prior Form 4 to include 2,917,169 shares of common stock reported as indirectly held through Canaan VIII L.P. The filing states these shares are held by Canaan LP, whose sole general partner is Canaan Partners VIII LLC; investment and voting decisions are made by the managers of Canaan LLC. The Reporting Person disclaims beneficial ownership except for any pecuniary interest from his LLC interest. No derivative securities are reported in this amendment.
Raman Singh, a director of Liquidia Corp (LQDA), exercised stock options and sold a portion of the resulting shares on 09/15/2025. He exercised a non-qualified option with a $2.51 strike to acquire 25,524 shares and a separate option with a $2.59 strike to acquire 20,000 shares. On the same date he sold 45,524 shares at a volume-weighted average price of $25.81, leaving him with beneficial ownership of 31,255 shares. The filing also discloses 18,396 restricted stock units granted on June 17, 2025 that had not vested as of the report date.
Insider sale notice for LQDA: The filing reports a proposed sale of 45,524 common shares on 09/15/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,175,042.73. The shares were acquired the same day via stock option exercise and paid for in cash. The filing shows 86,091,454 shares outstanding for the issuer. It also discloses a recent sale of 7,500 shares on 09/03/2025 generating $220,650.00 in gross proceeds. The signer certifies no undisclosed material adverse information.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
